News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Insider Information

Chinese Patent Reexamination Department partially invalidates Epigenomics’ patent claims for Septin9

PDF Berlin, 15 July 2019 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announced today that the Reexamination and Invalidation Department of the Patent office, China National Intellectual Property Administration (CNIPA) has, today, deemed Epigenomics’ Septin9 patent in China only partially valid. It has not been recognized for the detection of hepatocellular […]

Read more

CMS accepts Epigenomics’ application for NCD review

PDF Publication of Inside Information according to Article 17 MAR Berlin, 3 May 2019 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that the Centers for Medicare & Medicaid Services (CMS) has accepted the company’s application for a National Coverage Determination (NCD) review of Epi proColon, Epigenomics’ blood test for colorectal […]

Read more

Epigenomics AG terminates collaboration with Chinese licensing partner and announces anticipated revenue growth in 2019 outlook

PDF Publication of Inside Information according to Article 17 MAR Berlin, March 6, 2019 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) today has decided to terminate its collaboration with its Chinese partner BioChain for the licensing of the Septin9 marker and the exclusive distribution rights in China for Epi proColon, a […]

Read more

Epigenomics AG successfully completes capital increase; gross proceeds of EUR 22.3 million

PDF Publication of Inside Information according to Article 17 MAR Berlin, October 23, 2018 – Epigenomics AG (FSE: ECX; OTCQX: EPGNY) (“Company”) has fully placed the new shares from the capital increase resolved on October 7, 2018 of up to EUR 12,007,180 (corresponds to 50% of the existing share capital). Accordingly, the Company’s share capital […]

Read more

Epigenomics AG sets subscription price at EUR 1.86 per new share

PDF Publication of Inside Information according to Article 17 MAR Berlin, October 16, 2018 – The Executive Board of Epigenomics AG (FSE: ECX; OTCQX: EPGNY) (“Company”) resolved today, with approval of the Supervisory Board, to set the subscription price per new share at EUR 1.86 as part of the capital increase resolved on October 7, […]

Read more

Epigenomics AG plans to increase share capital with subscription rights for existing shareholders / Commitment of major shareholder to participate in planned capital increase

PDF Publication of Inside Information according to Article 17 MAR Berlin, October 3, 2018 – The Executive Board of Epigenomics AG (FSE: ECX; OTCQX: EPGNY) (“Company”) plans to execute a capital increase against contribution in cash and partly in kind with subscription rights for existing shareholders of up to 50% of the outstanding shares in […]

Read more